Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

January 01, 1996; Volume 49,Issue 1
  • You have access
    Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.
    A Schrattenholz, E F Pereira, U Roth, K H Weber, E X Albuquerque and A Maelicke
    Molecular Pharmacology January 1996, 49 (1) 1-6;
  • You have access
    Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes.
    E Nisoli, C Tonello, M Landi and M O Carruba
    Molecular Pharmacology January 1996, 49 (1) 7-14;
  • You have access
    Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B.
    H Kleinert, C Euchenhofer, I Ihrig-Biedert and U Förstermann
    Molecular Pharmacology January 1996, 49 (1) 15-21;
  • You have access
    Characterization of the G protein involved in the muscarinic stimulation of adenylyl cyclase of rat olfactory bulb.
    M C Olianas and P Onali
    Molecular Pharmacology January 1996, 49 (1) 22-29;
  • You have access
    Coexpression of beta 1 with cardiac sodium channel alpha subunits in oocytes decreases lidocaine block.
    J C Makielski, J T Limberis, S Y Chang, Z Fan and J W Kyle
    Molecular Pharmacology January 1996, 49 (1) 30-39;
  • You have access
    Ethanol increases the activity of large conductance, Ca(2+)-activated K+ channels in isolated neurohypophysial terminals.
    A M Dopico, J R Lemos and S N Treistman
    Molecular Pharmacology January 1996, 49 (1) 40-48;
  • You have access
    Palytoxin-induced Na+ influx into yeast cells expressing the mammalian sodium pump is due to the formation of a channel within the enzyme.
    J Redondo, B Fiedler and G Scheiner-Bobis
    Molecular Pharmacology January 1996, 49 (1) 49-57;
  • You have access
    Inhibition of human interferon-gamma biosynthesis by an antisense RNA-expressing vector.
    C M Boeve, A V Wyngaerd and M De Ley
    Molecular Pharmacology January 1996, 49 (1) 58-62;
  • You have access
    Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells.
    J D Schuetz, E G Schuetz, J V Thottassery, P S Guzelian, S Strom and D Sun
    Molecular Pharmacology January 1996, 49 (1) 63-72;
  • You have access
    Thiophosphorylation of the G protein beta subunit in human platelet membranes: evidence against a direct phosphate transfer reaction to G alpha subunits.
    M Hohenegger, T Mitterauer, T Voss, C Nanoff and M Freissmuth
    Molecular Pharmacology January 1996, 49 (1) 73-80;
  • You have access
    Protein kinase C isozyme-specific modulation of cyclic AMP-dependent phosphodiesterase in hypertrophic cardiomyopathic hamster hearts.
    J J Cai and H C Lee
    Molecular Pharmacology January 1996, 49 (1) 81-88;
  • You have access
    The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but is not essential for internalization.
    S A Laporte, G Servant, D E Richard, E Escher, G Guillemette and R Leduc
    Molecular Pharmacology January 1996, 49 (1) 89-95;
  • You have access
    Prolonged exposure to agonist results in a reduction in the levels of the Gq/G11 alpha subunits in cultured vascular smooth muscle cells.
    H Kai, T Fukui, B Lassègue, A Shah, C A Minieri and K K Griendling
    Molecular Pharmacology January 1996, 49 (1) 96-104;
  • You have access
    Stereoselective and regioselective hydration of 7-methylbenz[c]acridine-5,6-oxide enantiomers by rodent and human microsomal epoxide hydrolases.
    S J Roberts-Thomson, M E McManus, C C Duke, R Agnew and G M Holder
    Molecular Pharmacology January 1996, 49 (1) 105-111;
  • You have access
    Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor.
    D M Perez, J Hwa, R Gaivin, M Mathur, F Brown and R M Graham
    Molecular Pharmacology January 1996, 49 (1) 112-122;
  • You have access
    Effect of cyclothiazide on binding properties of AMPA-type glutamate receptors: lack of competition between cyclothiazide and GYKI 52466.
    M Kessler, A Arai, A Quan and G Lynch
    Molecular Pharmacology January 1996, 49 (1) 123-131;
  • You have access
    Single amino acid substitutions in the pm2 muscarinic receptor alter receptor/G protein coupling without changing physiological responses.
    D A Bulseco and M I Schimerlik
    Molecular Pharmacology January 1996, 49 (1) 132-141;
  • You have access
    Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655.
    K M Partin and M L Mayer
    Molecular Pharmacology January 1996, 49 (1) 142-148;
  • You have access
    Mitogenic effects of tetrahydrobiopterin in PC12 cells.
    P Z Anastasiadis, J C States, B A Imerman, M C Louie, D M Kuhn and R A Levine
    Molecular Pharmacology January 1996, 49 (1) 149-155;
  • You have access
    Specific and effective interaction of a guanine nucleotide analogue with small G proteins.
    S Hoffenberg, T M Shannon, T P Noonan, S Liu, D S Daniel, J B Fishman, J B Rubins, H K Misra, G E Wright and B F Dickey
    Molecular Pharmacology January 1996, 49 (1) 156-164;
  • You have access
    Structure-activity relationship of quaternary ammonium ions at the external tetraethylammonium binding site of cloned potassium channels.
    W Jarolimek, K V Soman, M Alam and A M Brown
    Molecular Pharmacology January 1996, 49 (1) 165-171;
  • You have access
    Phenytoin-initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation.
    P M Kim and P G Wells
    Molecular Pharmacology January 1996, 49 (1) 172-181;
  • You have access
    Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite.
    R B Clark, C Allal, J Friedman, M Johnson and R Barber
    Molecular Pharmacology January 1996, 49 (1) 182-189;
  • You have access
    Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists.
    S M Seiler, M Peluso, J G Tuttle, K Pryor, C Klimas, G R Matsueda and M S Bernatowicz
    Molecular Pharmacology January 1996, 49 (1) 190-197;
  • You have access
    The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine.
    R A Glennon, M Dukat, R B Westkaemper, A M Ismaiel, D G Izzarelli and E M Parker
    Molecular Pharmacology January 1996, 49 (1) 198-206;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 49, Issue 1
1 Jan 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics